We can outgrow biosimilar erosion curve,' Roche leaders tell anxious investors

While the likes of Amgen (Nasdaq: AMGN) and Johnson & Johnson (NYSE: JNJ) have already started to take the hit from competitors to big-selling biologics, looking ahead to the next two to three years, it is unlikely that the specter of biosimilars hangs over any company more than Roche (ROG: SIX).

So it is no wonder that executives of the Swiss pharma giant referred frequently to their confidence that the company can replace the revenue lost to these competitors when speaking to investors on Thursday, as well as reminding them that they had received a remarkable 31st consecutive annual dividend increase.

Daniel O’Day, chief executive of Roche Pharmaceuticals, said: “No other company has had to withstand such significant patent erosion and said “we have the confidence to grow through it.”